Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.
All News
Article
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.
Article
Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.
Article
Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.
Article
A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.
Article
The American College of Rheumatology (ACR) commended the limited extension of key Medicare telehealth coverage provisions but also expressed disappointment that Members of Congress have failed to pass measures to bring transparency to pharmacy benefit manager (PBM) practices, address flawed insur
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Article
Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).
Article
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).
Article
A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP).
Article
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Article
In October, the NEJM published a randomized clinical trial demonstrating the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1ra) in patients with obesity and knee osteoarthritis.
Article
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
Dr. John Cush
Tweet
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2
Dr. John Cush
Tweet
Systematic review of 14 studies using administrative/med. records data on >130 million people & 1 million dementia cases, finds the risk of Alzheimers/Dementia reduced w/ Antimicrobials, vaccines & NSAID antiinflammatories (but incr w/ DM drugs, vitamins, antipsychotics)… https://t.co/p79s5Pw4k2 https://t.co/9DO1WO2NuG
Dr. John Cush
Tweet
ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts Save
The ACR praised the limited extension of Medicare telehealth coverage but criticized Congress for not passing measures to increase transparency in PBM practices, address insurer issues, or prevent upcoming Medicare… https://t.co/pJ5f6LvELe https://t.co/jT3UJAx5It
Dr. John Cush
Tweet
U.S. overdose deaths far outpace other countries. In 2023 US drug overdoses >100,000 for 3rd year — a >50% jump since 2019. 2022 rate=324/1 million. High rates attributed to fentanyl, polysubstance use, counterfeit pills, variance in state policies on harm reduction… https://t.co/IYpytkEgpt https://t.co/HrrU9SCJT1
Dr. John Cush
Tweet
Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/0pIFM1Q2jO https://t.co/iGQ3ES7Nie
Dr. John Cush
Tweet
U.S. overdose deaths far outpace other countries. In 2023 US drug overdoses >100,000 for 3rd year — a >50% jump since 2019. 2022 rate=324/1 million. High rates attributed to fentanyl, polysubstance use, counterfeit pills, variance in state policies on harm reduction… https://t.co/oHtiMytdtR https://t.co/DLFPYEkdRC
Dr. John Cush
Tweet
Nipocalimab, a mAb that blocks FcRn, was granted a Priority Review from the FDA. J&J has submitted Biologics License Application (BLA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) myasthenia gravis based on Phase 3 Vivacity-MG3 study.… https://t.co/6sVbrgTBvF https://t.co/9a1dBWz87R
